Ryan Holmes

Company: Prelude Therapeutics​

Job title: Associate Director

Seminars:

Optimization From Standalone SMARCA2/4 Degrader Therapeutics to Potent ADC Payloads 3:00 pm

Explore the structure-activity optimization that enhanced potency of the early-stage SMARCA2 dual degrader lead Outline key modifications that enabled successful translation from oral drug to conjugated payload Discuss platform validation through proof-of-concept studiesRead more

day: Conference Day One